GSK PLC Statement: Zantac (ranitidine) litigation (1677U)

TIDMGSK

RNS Number : 1677U

GSK PLC

24 March 2023

Issued: 24 March 2023, London UK

Statement: Zantac (ranitidine) litigation

In response to yesterday's Sargon ruling by the California state court in respect of the Goetz case, GSK plc (LSE/NYSE: GSK) today issued the following statement:

GSK respectfully disagrees with this ruling by the California state court. Following the 13 epidemiological studies conducted looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer.

The litigation is still at an early stage and yesterday's decision relates only to the question of whether the plaintiff's experts can testify at trial in the Goetz case. It does not mean that the Court agrees with plaintiff's experts' scientific conclusions or their litigation-driven science. GSK will press additional defences and the plaintiff still needs to prove his case at trial.

This ruling does not affect other state cases or the December 2022 Daubert ruling made in the federal Multi-District Litigation.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com/company

 
GSK enquiries 
Media:               Tim Foley          [phone]      (London) 
                                         5502 
                     Dan Smith          [phone]      (London) 
                                         5502 
                     Kathleen Quinn     [phone]      (Washington DC) 
                     Lyndsay Meyer      [phone]      (Washington DC) 
 
Investor Relations:  Nick Stone         [phone]  (London) 
                     James Dodwell      [phone]      (London) 
                                         2406 
                     Mick Readey        [phone]  (London) 
                     Josh Williams      [phone]  (London) 
                     Camilla Campbell   [phone]  (London) 
                     Steph Mountifield  [phone]  (London) 
                     Jeff McLaughlin    [phone]      (Philadelphia) 
                     Frannie DeFranco   [phone]      (Philadelphia) 
 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2022, GSK's Q4 Results for 2022 and any impacts of the COVID-19 pandemic.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCPPUMAWUPWUBC

(END) Dow Jones Newswires

March 24, 2023 05:59 ET (09:59 GMT)